The catalysts for DXB SP surge were the partnerships because they signal independent stamp of confidence in the company...
That is exactly what the FDA approval means, even more than mere partnerships.
In my opinion, this CR by BOT was very badly timed and clearly smells like they wanted to give cheap shares to their mates before the SP took off on FDA approval.
Now the CR selling will dampen the momentum from the FDA approval.
Ann: FDA Approves Sofdra, page-234
-
- There are more pages in this discussion • 321 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.005(1.20%) |
Mkt cap ! $760.2M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 40.0¢ | $3.466M | 8.500M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 82195 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 301931 | 9 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |